Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
Beyond Air (NASDAQ: XAIR) reported fiscal Q3 2025 results with revenues of $1.1 million, showing a 34% increase from the previous quarter and 175% year-over-year growth. The company received CE Mark for LungFit PH in Europe and Market Authorization in Australia, expanding its global market presence.
Key developments include six new U.S. hospital starts in Q3, partnerships with two Middle East distributors, and a triggered $1 million milestone payment from Getz Healthcare. The company reported cash and equivalents of $10.9 million with total debt of $11.8 million. Cash runway is expected to extend well into 2026.
Operating expenses decreased significantly, with R&D expenses down to $3.0 million from $6.8 million year-over-year, and SG&A expenses reduced to $7.7 million from $9.8 million. The quarter's cash burn was $7.6 million.
Beyond Air (NASDAQ: XAIR) ha riportato i risultati del terzo trimestre fiscale 2025 con ricavi di 1,1 milioni di dollari, mostrando un aumento del 34% rispetto al trimestre precedente e una crescita del 175% su base annua. L'azienda ha ricevuto il marchio CE per LungFit PH in Europa e l'autorizzazione di mercato in Australia, espandendo la sua presenza sul mercato globale.
Sviluppi chiave includono sei nuove aperture in ospedali statunitensi nel terzo trimestre, partnership con due distributori del Medio Oriente e un pagamento di milione di dollari attivato da Getz Healthcare. L'azienda ha riportato liquidità e equivalenti pari a 10,9 milioni di dollari con un debito totale di 11,8 milioni di dollari. Si prevede che la liquidità si estenda bene oltre il 2026.
Le spese operative sono diminuite significativamente, con le spese per ricerca e sviluppo scese a 3,0 milioni di dollari rispetto ai 6,8 milioni di dollari dell'anno precedente, e le spese SG&A ridotte a 7,7 milioni di dollari rispetto ai 9,8 milioni di dollari. Il burn di cassa per il trimestre è stato di 7,6 milioni di dollari.
Beyond Air (NASDAQ: XAIR) informó resultados del tercer trimestre fiscal 2025 con ingresos de 1,1 millones de dólares, mostrando un aumento del 34% en comparación con el trimestre anterior y un crecimiento del 175% interanual. La empresa recibió el marcado CE para LungFit PH en Europa y la autorización de mercado en Australia, ampliando su presencia en el mercado global.
Los desarrollos clave incluyen seis nuevas inauguraciones en hospitales de EE. UU. en el tercer trimestre, asociaciones con dos distribuidores de Medio Oriente y un pago de hito de un millón de dólares activado por Getz Healthcare. La empresa reportó efectivo y equivalentes de 10,9 millones de dólares con una deuda total de 11,8 millones de dólares. Se espera que el capital dure bien hasta 2026.
Los gastos operativos disminuyeron significativamente, con gastos de I+D reducidos a 3,0 millones de dólares desde 6,8 millones de dólares interanuales, y los gastos de SG&A reducidos a 7,7 millones de dólares desde 9,8 millones de dólares. La quema de efectivo del trimestre fue de 7,6 millones de dólares.
비욘드 에어 (NASDAQ: XAIR)는 2025 회계 연도 3분기 결과를 보고하며 매출이 110만 달러로 이전 분기 대비 34% 증가하고 전년 동기 대비 175% 성장했다고 발표했습니다. 이 회사는 유럽에서 LungFit PH에 대한 CE 마크를 받았고 호주에서 시장 승인을 받아 글로벌 시장에서의 입지를 확장하고 있습니다.
주요 발전사항으로는 3분기에 미국 병원에서의 새 개시 6건, 중동 두 배급업체와의 파트너십, Getz Healthcare로부터의 100만 달러의 이정표 지급이 포함됩니다. 이 회사는 현금 및 현금성 자산이 1090만 달러이며 총 부채는 1180만 달러라고 보고했습니다. 현금 유동성은 2026년까지 지속될 것으로 예상됩니다.
운영 비용은 크게 감소했으며, 연구 개발 비용이 전년 대비 680만 달러에서 300만 달러로 줄어들었고, SG&A 비용은 980만 달러에서 770만 달러로 감소했습니다. 이 분기의 현금 소진은 760만 달러였습니다.
Beyond Air (NASDAQ: XAIR) a annoncé ses résultats du troisième trimestre fiscal 2025 avec des revenus de 1,1 million de dollars, affichant une augmentation de 34 % par rapport au trimestre précédent et une croissance de 175 % d'une année sur l'autre. L'entreprise a reçu le marquage CE pour LungFit PH en Europe et l'autorisation de mise sur le marché en Australie, étendant ainsi sa présence sur le marché mondial.
Les développements clés comprennent six nouvelles ouvertures d'hôpitaux aux États-Unis au troisième trimestre, des partenariats avec deux distributeurs au Moyen-Orient et un paiement d'étape de 1 million de dollars déclenché par Getz Healthcare. L'entreprise a rapporté des liquidités et équivalents de 10,9 millions de dollars avec une dette totale de 11,8 millions de dollars. La trésorerie est prévue pour durer bien jusqu'en 2026.
Les frais d'exploitation ont diminué de manière significative, les dépenses de R&D étant passées de 6,8 millions de dollars à 3,0 millions de dollars d'une année sur l'autre, et les dépenses SG&A ont été réduites à 7,7 millions de dollars, contre 9,8 millions de dollars. La consommation de trésorerie du trimestre était de 7,6 millions de dollars.
Beyond Air (NASDAQ: XAIR) berichtete über die Ergebnisse des dritten Quartals 2025 mit Einnahmen von 1,1 Millionen Dollar, was einem Anstieg von 34 % gegenüber dem vorherigen Quartal und einem Wachstum von 175 % im Jahresvergleich entspricht. Das Unternehmen erhielt das CE-Zeichen für LungFit PH in Europa und die Marktzulassung in Australien, wodurch es seine globale Marktpräsenz ausweitete.
Zu den wichtigsten Entwicklungen gehören sechs neue Krankenhausanfänge in den USA im dritten Quartal, Partnerschaften mit zwei Distributoren im Nahen Osten und eine ausgelöste Meilensteinzahlung von 1 Million Dollar von Getz Healthcare. Das Unternehmen berichtete über liquide Mittel und Zahlungsmitteläquivalente von 10,9 Millionen Dollar bei einer Gesamtverschuldung von 11,8 Millionen Dollar. Die Liquidität wird voraussichtlich bis weit ins Jahr 2026 reichen.
Die Betriebskosten sind deutlich gesunken, wobei die F&E-Ausgaben von 6,8 Millionen Dollar im Jahresvergleich auf 3,0 Millionen Dollar gesenkt wurden, und die SG&A-Ausgaben von 9,8 Millionen Dollar auf 7,7 Millionen Dollar reduziert wurden. Der Cash-Burn des Quartals betrug 7,6 Millionen Dollar.
- Revenue growth of 34% quarter-over-quarter to $1.1 million
- CE Mark approval for LungFit PH in Europe
- Market authorization secured in Australia
- Six new U.S. hospital implementations in Q3
- $1 million milestone payment from Getz Healthcare partnership
- Significant reduction in operating expenses
- Cost of revenue ($1.3M) exceeded revenue ($1.1M)
- Quarterly cash burn of $7.6 million
- Other expenses increased by $2.1 million due to debt retirement loss
Insights
Beyond Air's Q3 FY2025 results reveal a complex financial picture with both promising developments and ongoing challenges. Revenue reached
Key Financial Metrics:
- Cost of revenue at
$1.3 million exceeds revenue, primarily due to device depreciation and one-time upgrade costs - Reduced operating expenses: R&D down
$3.8 million YoY, SG&A decreased$2.1 million - Quarterly cash burn of
$7.6 million with$10.9 million cash on hand
Strategic Growth Catalysts:
- CE Mark approval opens significant European market opportunity
- Australian market authorization and Middle East partnerships expand global footprint
- Cardiac surgery PMA supplement under FDA review could accelerate market penetration
The company's cash conservation strategy, coupled with anticipated revenue growth and debt repayment starting October 2026, provides a runway into 2026. However, reaching profitability will require significant revenue scaling. The international expansion through distribution partnerships could accelerate commercialization compared to the U.S. trajectory, potentially improving the path to positive cash flow.
Revenues increased
Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year
Conference call at 4:30 p.m. ET today, February 10th
GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced its financial results for the fiscal third quarter ended December 31, 2024, and provided a corporate update.
“Our commercial team continues to make significant progress as we expand the number of U.S. hospitals utilizing LungFit PH. While this is the culmination of years of work, it was approximately nine months ago that we started to make significant headway in our commercial efforts with the fully updated system. We expect to continue generating double digit sequential quarterly revenue growth for the foreseeable future,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air.
“We ended calendar year 2024 on a high note with the receipt of CE Mark for LungFit PH in Europe, opening a significant portion of the global market outside of the U.S. for our current and future distribution partners to launch their commercial programs for LungFit PH. With the advantage of real-world customer experience and feedback from our U.S. program, combined with our distribution partners’ established sales teams and customer networks, we anticipate a faster commercial ramp-up in these regions compared to what we experienced in the U.S.,” concluded Mr. Lisi.
Commercial Execution, Portfolio Highlights and Upcoming Milestones
- LungFit® PH Commercial Execution
- Increased demand for LungFit PH:
- A
34% increase in revenue for the quarter ended December 31, 2024, compared with the quarter ended September 30, 2024 - Six new hospital starts in the U.S. in the quarter ended December 31, 2024
- A
- Received market authorization in Australia in January 2025 and expect to have regulatory approvals in eight countries covered under the partnership with Getz Healthcare by calendar year-end, with initial commercial shipments occurring in 2025.
- Signed partnerships with two distributors in the Middle East in January 2025, with initial shipments expected in the 1H of calendar year 2025.
- Increased demand for LungFit PH:
- Pipeline Highlights
- Received CE Mark for LungFit PH, which allows Beyond Air to market LungFit PH in the European Union and all other countries that recognize this certification.
- Indications under CE Mark certification include:
- The treatment of infants >34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation; and
- The treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function
- CE Mark certification triggered a
$1 million milestone payment, payable in the fiscal fourth quarter of 2025, from the Company’s Asia-Pacific partner, Getz Healthcare, the leading distributor of medical equipment, devices and consumables in Asia Pacific region – providing access to hospitals in Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore and Vietnam- Beyond Air will also receive double-digit royalty payments based on LungFit PH net sales by Getz Healthcare
- Indications under CE Mark certification include:
- Cardiac surgery PMA supplement review ongoing at FDA
- Currently no FDA approved nitric oxide system is labeled for cardiac surgery
- Approval should increase LungFit PH’s rate of market penetration
- LungFit PH transport-ready PMA supplement submission to FDA anticipated in the coming months
- Received CE Mark for LungFit PH, which allows Beyond Air to market LungFit PH in the European Union and all other countries that recognize this certification.
Beyond Cancer - Solid Tumor Program
- Clinical Development Execution
- Phase 1a trial (monotherapy) - Part A of the trial evaluating ultra-high concentration Nitric Oxide (UNO) therapy in subjects with advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors at a dose of 25,000 ppm has been completed, and at the dose of 50,000 ppm is ongoing.
- Phase 1b trial (combination therapy) - Received regulatory approval in Israel for Part B of the trial, which will assess the intratumoral administration of 25,000 ppm low volume (LV) Nitric Oxide (UNO) in patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions, who have shown disease progression or prolonged stable disease (12 weeks) after receiving a single agent anti-PD-1 containing treatment. Topline data from the Phase 1b portion of the study are anticipated late in calendar 2025 or early-2026.
NeuroNOS – Autism Spectrum Disorder (ASD) Program
- NeuroNOS appointed Professor Roger D. Kornberg to its Scientific Advisory Board (SAB). Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his groundbreaking work in molecular biology and is a renowned leader in the field of eukaryotic gene transcription. Professor Kornberg will assist NeuroNOS in accelerating the development of treatments for ASD and potentially other neurological disorders.
Financial Results for the Fiscal Third Quarter Ended December 31, 2024
Revenues for the fiscal quarter ended December 31, 2024 were
Cost of revenue of
Research and development expenses for the three months ended December 31, 2024 were
Selling, general and administrative expenses for the three-month periods ended December 31, 2024 and 2023 were
Other expense for the three months ended December 31, 2024 was
Cash burn in the fiscal quarter ended December 31, 2024, excluding the impacts of financing and the extinguishment of debt, was
As of December 31, 2024, the Company reported cash, cash equivalents, and marketable securities of
Conference Call & Webcast
Monday, February 10th @ 4:30 PM ET
| Domestic: | 1-877-407-0784 | |
| International: | 1-201-689-8560 | |
| Conference ID: | 13750714 | |
| Webcast: | A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online recording of the conference call will be available on the Company’s website or via the direct link an hour after the call. |
About Beyond Air®, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
About LungFit® *
Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
*Beyond Air’s LungFit PH is approved for commercial use in the United States of America, European Union, Australia and New Zealand. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About PPHN
Persistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–
About Beyond Cancer, Ltd.
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in patients with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols.
For more information, visit www.beyondcancer.com.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
BEYOND AIR, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share and per share data)
| December 31, 2024 | March 31, 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 4,601 | $ | 11,378 | ||||
| Marketable securities | 6,349 | 23,090 | ||||||
| Restricted cash | 232 | 230 | ||||||
| Accounts receivable, net | 639 | 319 | ||||||
| Inventory, net | 2,379 | 2,127 | ||||||
| Other current assets and prepaid expenses | 5,144 | 6,792 | ||||||
| Total current assets | 19,344 | 43,936 | ||||||
| Licensed right to use technology | 1,274 | 1,427 | ||||||
| Right-of-use lease assets | 1,775 | 2,121 | ||||||
| Property and equipment, net | 11,652 | 9,364 | ||||||
| Other assets | 100 | 113 | ||||||
| TOTAL ASSETS | $ | 34,144 | $ | 56,961 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 2,357 | $ | 1,948 | ||||
| Accrued expenses and other current liabilities | 2,631 | 8,402 | ||||||
| Operating lease liability, current portion | 381 | 418 | ||||||
| Loans payable, current portion | 60 | 800 | ||||||
| Total current liabilities | 5,430 | 11,567 | ||||||
| Operating lease liability, net | 1,567 | 1,898 | ||||||
| Long-term debt, net | - | 14,721 | ||||||
| Long-term liability, related party | 8,710 | - | ||||||
| Warrant liability | 56 | 275 | ||||||
| Derivative liability | - | 1,314 | ||||||
| Total liabilities | 15,763 | 29,775 | ||||||
| Stockholders’ equity | ||||||||
| Preferred Stock, | - | - | ||||||
| Common Stock, | 7 | 5 | ||||||
| Treasury stock | (25 | ) | (25 | ) | ||||
| Additional paid-in capital | 296,000 | 264,780 | ||||||
| Accumulated deficit | (278,288 | ) | (239,697 | ) | ||||
| Accumulated other comprehensive income (loss) | (51 | ) | (15 | ) | ||||
| Total stockholders’ equity attributable to Beyond Air, Inc | 17,644 | 25,048 | ||||||
| Non-controlling interest | 738 | 2,138 | ||||||
| Total equity | 18,381 | 27,186 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 34,144 | $ | 56,961 | ||||
BEYOND AIR, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(amounts in thousands, except share and per share data)
(UNAUDITED)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues | $ | 1,072 | $ | 391 | $ | 2,553 | $ | 689 | ||||||||
| Cost of revenues | 1,287 | 748 | 4,184 | 1,483 | ||||||||||||
| Gross loss | (215 | ) | (356 | ) | (1,631 | ) | (794 | ) | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | (3,005 | ) | (6,838 | ) | (13,599 | ) | (18,664 | ) | ||||||||
| Selling, general and administrative | (7,732 | ) | (9,768 | ) | (22,133 | ) | (30,915 | ) | ||||||||
| Total Operating expenses | (10,737 | ) | (16,606 | ) | (35,732 | ) | (49,578 | ) | ||||||||
| Loss from Operations | (10,952 | ) | (16,963 | ) | (37,363 | ) | (50,372 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Dividend/investment income | 126 | 388 | 637 | 1,438 | ||||||||||||
| Interest and finance expense | (549 | ) | (919 | ) | (2,439 | ) | (1,991 | ) | ||||||||
| Change in fair value of warrant liability | 4 | 46 | 219 | 693 | ||||||||||||
| Change in fair value of derivative liability | - | 135 | 1,314 | 1,147 | ||||||||||||
| Foreign exchange gain/ (loss) | 46 | 31 | (26 | ) | (3 | ) | ||||||||||
| Loss on extinguishment of debt | (1,910 | ) | - | (2,534 | ) | - | ||||||||||
| Loss on disposal of fixed assets | (62 | ) | - | (233 | ) | - | ||||||||||
| Estimated liability for contingent loss | - | (11 | ) | - | (609 | ) | ||||||||||
| Other income / (expense) | (37 | ) | 35 | 11 | (42 | ) | ||||||||||
| Total other income/ (expense) | (2,381 | ) | (294 | ) | (3,052 | ) | 633 | |||||||||
| Net loss before income taxes | $ | (13,333 | ) | $ | (17,258 | ) | $ | (40,416 | ) | $ | (49,739 | ) | ||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (13,333 | ) | $ | (17,258 | ) | $ | (40,416 | ) | $ | (49,739 | ) | ||||
| Less : net loss attributable to non-controlling interest | (300 | ) | (1,038 | ) | (1,825 | ) | (3,204 | ) | ||||||||
| Net loss attributable to Beyond Air, Inc. | (13,032 | ) | (16,220 | ) | (38,591 | ) | (46,535 | ) | ||||||||
| Foreign currency translation loss | (61 | ) | (9 | ) | (37 | ) | (19 | ) | ||||||||
| Comprehensive loss attributable to Beyond Air, Inc. | $ | (13,093 | ) | $ | (16,229 | ) | $ | (38,628 | ) | $ | (46,554 | ) | ||||
| Net basic and diluted loss per share attributable to Beyond Air, Inc. | $ | (0.15 | ) | $ | (0.50 | ) | $ | (0.64 | ) | $ | (1.46 | ) | ||||
| Weighted average number of shares, outstanding, basic and diluted | 88,074,511 | 32,462,476 | 60,417,218 | 31,883,799 | ||||||||||||
FAQ
What was Beyond Air's (XAIR) revenue growth in Q3 2025?
How many new hospitals started using XAIR's LungFit PH in Q3 2025?
What is XAIR's cash position as of December 31, 2024?
When will XAIR begin international shipments following CE Mark approval?
What regulatory approvals did XAIR receive in Q3 2025?
